A drug called tirzepatide and sold under the name Zepbound has been approved by the US Food and Drug Administration for use as a weight-loss medication
A weight-loss drug called tirzepatide has received approval from the US Food and Drug Administration for adults who are overweight or have obesity and at least one weight-related condition, such as high blood pressure or type 2 diabetes. In clinical trials, it reduced body weight by an average of almost 21 per cent in people who were overweight or had obesity.
“With rising rates of obesity, there’s been an increased demand for medications indicated for weight management, and we have faced shortages in the past,” saysTirzepatide, sold under the brand name Zepbound, is a once-weekly injection that mimics two hormones: GLP-1 and GIP. The body naturally produces GIP once we start eating, which increases hunger, and then releases GLP-1 after
eating to trigger the sensation of fullness, says Aronne. “For reasons we still don’t understand, when you give along with GLP-1, it reduces appetite even further,” he says.by Aronne and his colleagues, more than 2500 adults with obesity, but not diabetes, took either a placebo or a low, medium or high dose of tirzepatide for 72 weeks. People given the highest dose lost, on average, nearly 21 per cent of their body weight, or almost 24 kilograms.
For many people with obesity, the health benefits of tirzepatide outweigh its potential downsides. “One of the best outcomes can be reversing complications that are associated with ,” says Jaisinghani. “By reversing some of those complications we now have an opportunity to potentially take people off other medications, and this not only improves their health, but their quality of life.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New weight loss drug: FDA approves Zepbound, a version of diabetes drug Mounjaro for obesityZepbound, a new version of the popular diabetes treatment Mounjaro, can now be sold as a weight-loss drug and helped patients lose 25% of their weight.
Read more »
FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, or tirzepatide.
Read more »
Eli Lilly Stock Jumps on Obesity Drug's FDA ApprovalThe drug will be marketed as an obesity treatment under the name Zepbound.
Read more »
FDA Approves Weight Loss Drug Zepbound, Similar to OzempicBerkeley Lovelace Jr. is a health and medical news reporter for NBC News.
Read more »
Eli Lilly weight loss drug Zepbound approved by the FDADiabetes Drug Leads To, Significant Weight Loss in Those With Obesity, Study Finds. Researchers with Yale University recently published the results of their study in the 'New England Journal of Medicine.'. The diabetes drug tirzepatide was the focus of the study, which also included calorie restriction and 150 minutes of weekly exercise.
Read more »
What to know about Zepbound, the newest weight-loss drugThe new weight-loss drug has been approved by the U.S. Food and Drug Administration to treat obesity.
Read more »